Eleven Biotherapeutics stock soared on Monday following news of its deal with Roche concerning its Interleukin-6 technology. More
- ADVERTISEMENT
- ADVERTISEMENT
-
- Poll of the Day
- Partners
- ADVERTISEMENT
RHHBY
Recent Articles
Johnson & Johnson: My Favorite Dividend King (JNJ)
Johnson & Johnson is one of the strongest dividend payers the market's have to offer. Here's why I'm willing to pay a premium to own JNJ stock More
How Big Data & Big Pharma Will Transform Drug Development
Big data can be used by big pharma companies like Roche to drastically cut costs, increase drug production and drive long-term stock gains. More
U.S. Debut of Biosimilar Drugs Threatens Major Biotechs
The introduction of biosimilar drugs will change the biotech landscape ... especially for these three names. More
10 Healthcare Stocks Taking Aim at Cancer
Amgen, Inc. (NASDAQ:AMGN), Celgene Corporation (NASDAQ:CELG), Inovio Pharmaceuticals Inc. (NASDAQ:INO) and several other healthcare stocks are cancer medicine plays worth a look. More
Will Lower Oil Mean Higher Q4 Earnings?
With Q4 earnings season upon us, better-than-expected gains from companies based partly or mostly on lower oil prices may be just the salve the market needs to regain some traction. More
Add Roche to Your List of Ebola Stocks, But …
Ebola stocks have doled out some big gains to savvy traders this year, but investors looking for Roche (RHHBY) to do the same may want to rethink their expectations. More
